The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksMedium•16 April 2026•

1 min read

Achieve Life Sciences Shifts Cytisinicline Production to Ohio Amid FDA Refiling Plans

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1Achieve Life Sciences completed the transfer of cytisinicline manufacturing to Adare Pharma Solutions in Ohio.

Achieve Life Sciences has successfully completed the manufacturing transfer of its nicotine-dependence drug, cytisinicline, to Adare Pharma Solutions in Ohio. This strategic relocation follows an Official Action Indicated (OAI) classification from the FDA regarding a previous third-party manufacturing site. By shifting production to a U.S.-based facility, the company aims to mitigate regulatory risks and ensure supply chain redundancy ahead of its commercial goals. Achieve Life Sciences now expects to resubmit its New Drug Application (NDA) in the fourth quarter of 2026. This move is viewed as a critical step in resolving previous compliance bottlenecks that had clouded the drug's path to market. The company remains focused on a planned commercial launch in 2027, contingent upon regulatory approval.